Noteworthy Rating Filing: Analysts at Jefferies Kept their “Hold” rating for Mediclinic International (LON:MDC) with GBX 741.00 Target Price

November 29, 2016 - By Marguerite Chambers

Mediclinic International (LON:MDC) Rating

In an analyst report issued to investors and clients on today, Jefferies maintained their “Hold” rating on Mediclinic International (LON:MDC)‘s stock. The price target gives a potential upside of 5.56% from company’s close price.

Mediclinic International PLC (LON:MDC) Ratings Coverage

Out of 10 analysts covering Mediclinic International (LON:MDC), 3 rate it a “Buy”, 1 “Sell”, while 6 “Hold”. This means 30% are positive. GBX 1170 is the highest target while GBX 741 is the lowest. The GBX 939.50 average target is 33.93% above today’s (GBX 701.51) stock price. Mediclinic International has been the topic of 19 analyst reports since February 18, 2016 according to StockzIntelligence Inc. The company was downgraded on Monday, September 12 by Citigroup. The rating was maintained by Macquarie Research on Friday, May 27 with “Neutral”. HSBC maintained it with “Reduce” rating and GBX 745 target price in Friday, November 11 report. On Thursday, September 22 the stock rating was maintained by Jefferies with “Hold”. On Wednesday, November 23 the stock rating was maintained by Macquarie Research with “Neutral”. The stock of Mediclinic International PLC (LON:MDC) has “Buy” rating given on Monday, November 21 by UBS. Jefferies maintained it with “Hold” rating and GBX 741 target price in Tuesday, November 29 report. On Tuesday, September 6 the stock rating was maintained by UBS with “Buy”. The firm has “Neutral” rating by JP Morgan given on Tuesday, August 23. The stock of Mediclinic International PLC (LON:MDC) earned “Neutral” rating by Citigroup on Thursday, February 18.

The stock decreased 2.90% or GBX 20.99 on November 29, hitting GBX 701.51. About 2.15 million shares traded hands or 27.22% up from the average. Mediclinic International PLC (LON:MDC) has declined 20.17% since May 2, 2016 and is downtrending. It has underperformed by 25.43% the S&P500.

Analysts await M.D.C. Holdings, Inc. (NYSE:MDC) to report earnings on February, 1. They expect $0.71 EPS, up 54.35% or $0.25 from last year’s $0.46 per share. MDC’s profit will be $34.79M for 9.49 P/E if the $0.71 EPS becomes a reality. After $0.54 actual EPS reported by M.D.C. Holdings, Inc. for the previous quarter, Wall Street now forecasts 31.48% EPS growth.

Insitutional Activity: The institutional sentiment increased to 1.22 in Q2 2016. Its up 0.39, from 0.83 in 2016Q1. The ratio improved, as 26 funds sold all Mediclinic International PLC shares owned while 62 reduced positions. 21 funds bought stakes while 52 increased positions. They now own 38.01 million shares or 0.55% more from 37.80 million shares in 2016Q1.

Alliancebernstein Ltd Partnership accumulated 87,022 shares or 0% of the stock. Pitcairn last reported 12,215 shares in the company. Vanguard Inc owns 3.16M shares or 0% of their US portfolio. Brandes Invest Prtn L P has 1.37M shares for 0.51% of their US portfolio. Echo Street Cap Mngmt Ltd Liability last reported 0.23% of its portfolio in the stock. Swiss National Bank & Trust last reported 65,000 shares in the company. Moreover, Pinnacle Ltd Llc has 0% invested in Mediclinic International PLC (LON:MDC) for 33,052 shares. Old Mutual (Uk) reported 139,105 shares or 0.06% of all its holdings. New York State Common Retirement Fund last reported 0% of its portfolio in the stock. Aqr Capital Management Limited has 0.01% invested in the company for 142,162 shares. Geode Capital Mngmt Limited Liability Corporation, a Massachusetts-based fund reported 265,343 shares. Moreover, Blackrock Ltd Liability has 0% invested in Mediclinic International PLC (LON:MDC) for 18,558 shares. Group One Trading Ltd Partnership owns 4,106 shares or 0% of their US portfolio. Hexavest Incorporated holds 557,560 shares or 0.21% of its portfolio. Tudor Invest Et Al holds 0% of its portfolio in Mediclinic International PLC (LON:MDC) for 8,800 shares.

Mediclinic International plc, formerly Al Noor Hospitals Group plc, is a holding company. The company has a market cap of 5.17 billion GBP. The Firm operates as an international private healthcare provider. It has a 25.65 P/E ratio. The Company’s divisions include Mediclinic Southern Africa, Mediclinic Switzerland, Mediclinic Middle East, United Kingdom and Corporate.

According to Zacks Investment Research, “M.D.C. HOLDINGS, INC. is engaged in the construction, sale and related financing of residential housing and the acquisition and development of land for use in its homebuilding activities and sale to others, in the Denver, Phoenix, Maryland, Virginia, mid Atlantic region, Las Vegas, Dallas, California metropolitan areas. They are also is involved in real estate brokerage, property management, condominium conversions and fee construction of apartment and commercial buildings.”

MDC Company Profile

M.D.C. Holdings, Inc., incorporated on May 17, 1985, is engaged in two primary operations, including homebuilding and financial services. The Company’s homebuilding activities consist of subsidiary companies that purchases finished lots or develop lots for the construction and sale primarily of single-family detached homes to first-time and first-time move-up homebuyers under the name Richmond American Homes. The Company’s homebuilding activities consists of various homebuilding divisions that the Company considers to be its operating divisions. The Company’s operating divisions include West (include operating divisions located in Arizona, California, Nevada and Washington); Mountain (include operating divisions located in Colorado and Utah), and East (include operating divisions located in Virginia, Florida and Maryland, which include Pennsylvania, and New Jersey).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>